Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury
OwnerGuillaume Hoareau, Robin M. Shawinventors
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of ischemia-reperfusion injury in a subject using GJA1-20k as a therapeutic agent. In one embodiment, the compositions and methods comprise a GJA1-20k peptide therapy. In another embodiment, the compositions and methods comprise a GJA1-20k gene therapy. In some embodiments, the GJA1-20k therapy comprises truncated forms of GJA1-20k. In some embodiments, the GJA1-20k therapy mitigates mitochondrial stress and dysfunction.
Claims21
A method of treating, preventing, reducing the likelihood of having, reducing the severity of, and/or slowing the progression of ischemia-reperfusion injury in a subject, the method comprising:
- administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:
- a GJA1-20k polypeptide or functional variant or fragment thereof;
- or
- a GJA1-20k gene expression vector comprising a polynucleotide sequence encoding a GJA1-20k polypeptide or functional variant or fragment thereof.
6-7. (canceled)
A pharmaceutical composition comprising a GJA1-20k polypeptide or functional variant or fragment thereof.
A pharmaceutical composition comprising a GJA1-20k gene expression vector comprising a polynucleotide sequence encoding a GJA1-20k polypeptide or functional variant or fragment thereof.
22-25. (canceled)
Dependencies are inferred from the claim text.